Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.

• Published in: PLoS Neglected Tropical Diseases
• Main Authors: Asrat Hailu, Ahmed Musa, Monique Wasunna, Manica Balasegaram, Sisay Yifru, Getahun Mengistu, Zewdu Hurissa, Workagegnehu Hailu, Teklu Weldegebreal, Samson Tesfaye, Eyasu Makonnen, Eltahir Khalil, Osama Ahmed, Ahmed Fadlalla, Ahmed El-Hassan, Muzamil Raheem, Marius Mueller, Yousif Koummuki, Juma Rashid, Jane Mbui, Geoffrey Mucee, Simon Njoroge, Veronica Manduku, Alice Musibi, Geoffrey Mutuma, Fredrick Kirui, Hudson Lodenyo, Dedan Mutea, George Kirigi, Tansy Edwards, Peter Smith, Lawrence Muthami, Catherine Royce, Sally Ellis, Moses Alobo, Raymond Omollo, Josephine Kesusu, Rhoda Owiti, John Kinuthia, Leishmaniasis East Africa Platform (LEAP) group
• Format: Article in Journal/Newspaper
• Language: English
• Published: Public Library of Science (PLoS) 2010
• Subjects: Arctic medicine. Tropical medicine; RC955-962; Public aspects of medicine; RA1-1270; Arctic
• Online Access: https://doi.org/10.1371/journal.pntd.0000709; https://doaj.org/article/a53d30a0c578481b92f81187f981e8ec

Visceral leishmaniasis (VL) is a major health problem in developing countries. The untreated disease is fatal, available treatment is expensive and often toxic, and drug resistance is increasing. Improved treatment options are needed. Paromomycin was shown to be an efficacious first-line treatment with low toxicity in India.This was a 3-arm multicentre, open-label, randomized, controlled clinical trial to compare three treatment regimens for VL in East Africa: paromomycin sulphate (PM) at 15 mg/kg/day for 21 days versus sodium stibogluconate (SSG) at 20 mg/kg/day for 30 days; and the combination of both dose regimens for 17 days. The primary efficacy endpoint was cure based on parasite-free tissue aspirates taken 6 months after treatment.Overall, 135 patients per arm were enrolled at five centres in Sudan (2 sites), Kenya (1) and Ethiopia (2), when the PM arm had to be discontinued due to poor efficacy. The trial has continued with the higher dose of PM as well as the combination of PM and SSG arms. These results will be reported later. Baseline patient characteristics were similar among treatment arms. The overall cure with PM was significantly inferior to that with SSG (63.8% versus 92.2%; difference 28.5%, 95%CI 18.8% to 38.8%, p<0.001). The efficacy of PM varied among centres and was significantly lower in Sudan (14.3% and 46.7%) than in Kenya (80.0%) and Ethiopia (75.0% and 96.6%). No major safety issues with PM were identified.The efficacy of PM at 15 mg/kg/day for 21 days was inadequate, particularly in Sudan. The efficacy of higher doses and the combination treatment warrant further studies.